The approval came in final guidance issued today by the institute.
GPs will be able to prescribe golimumab (Simponi) in limited circumstances, typically when a patient’s condition has not responded to conventional disease-modifying antirheumatic drugs.
But they must also fulfil a range of other criteria before the drug can be prescribed.
Dr Carole Longson, director of NICE’s Health Technology Evaluation Centre, said: ‘Rheumatoid arthritis treatments help to relieve pain, improve mobility and reduce the long-term damage often experienced by people with this condition.
'NICE has already recommended seven treatment options for patients living with this very disabling disease; now golimumab is another option.’
Click here to read the full guidance, including prescribing criteria